Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Search results for

There are 22,114 results that match your search.22,114 results
  • The TIPO's accelerated examination programme (AEP) has been in operation for over six years since the launch of its pilot version in 2009. According to a statistics report of the TIPO, by the end of November 2015, the conditions for requesting AEP and the average corresponding examination time are as follows:
  • Myanmar's general election, which took place on November 8, was the first nationwide vote since the military junta's dissolution in 2011. It was also the first poll contested by opposition party the National League for Democracy (NLD) in 25 years. Rapid economic reforms since 2011 have resulted in enormous growth opportunities. With the NLD winning a sweeping majority in both houses of parliament, the country now enters a transitional phase with the quasi-civilian government gradually transferring power to the NLD.
  • The US Supreme Court issued two rulings on trade mark cases in 2015, but the most significant opinion may have come from the Federal Circuit, when it issued a split en banc ruling in The Slants case
  • In recent years, the ITC and Federal Circuit slowly closed the door on the assertion of method claims at the ITC. The Suprema decision reversed the trend, but may have opened the door wide enough for direct infringement claims to again pass through, argue John Haynes and Adam D Swain
  • Genentech, the plaintiff, owns a patent for an invention titled "vascular endothelial cell growth factor antagonists". Genentech filed an application for the registration of patent term extension in relation to the patent asserting that Genentech obtained an approval of partial changes in manufacturing approval (the disposition), which added a new dosage and administration for its medicine Avastin, whose general name is bevacizumab (the medicine). Regarding the medicine, there was a prior disposition that differs only in dosage and administration.
  • The debate over the patentability of isolated DNA has raged around the world. Tania Obranovich compares the two Myriad decisions from the highest courts in Australia and the US and explains how the Australian decision has called into question what had long been thought of as a fundamental pillar of Australian patent law
  • This month we take a detour from trade mark issues to cover recent developments in data privacy, a subject that has been the focus of considerable attention from Chinese regulators over the past few years. On September 29 2015, China's National People's Congress promulgated the Ninth Amendment to the PRC Criminal Law, broadening the scope of protection afforded to citizens' personal information, while also inserting new provisions aimed at combating online fraud, pornography and other illegal online content.
  • In 2010, the EPO introduced the PACE programme, which allowed applicants to accelerate prosecution of patent applications pending before the EPO. Under the PACE programme, the EPO would make every effort to issue a first examination communication within three months of the PACE request.
  • In June 2015, in a case concerning patent validity, the French Supreme Court (Cour de cassation) issued a decision (Cass Com 13-15.862) relating to confidentiality obligations to prevent any risk of public disclosure in an inter partes relationship:
  • On March 23 2016 the new Trade Mark Regulation 2015/2424 will enter into force. This Regulation is the result of the European Commission's pledge to make the new trade mark registration system more accessible, efficient, flexible, reliable and predictable.